The Global Infertility Drugs Market is driven by increasing number...

The Global Infertility Drugs Market is driven by increasing number of couples opting for IVF treatments

Postado 2024-02-20 11:11:39

The global infertility drugs market has witnessed significant growth over the past few years owing to the growing trend of late pregnancies and rising number of fertility clinics worldwide. Infertility drugs help stimulate ovulation through hormonal therapies and medications. They induce ovulation and promote the release of luteinizing hormone and follicle-stimulating hormone. Common infertility drugs include clomiphene citrate, gonadotropins, aromatase inhibitors, and progesterone supplements. The increasing prevalence of polycystic ovary syndrome (PCOS), endometriosis, and testicular dysfunction among others has boosted the demand for these drugs. Moreover, rising acceptance of reproductive technologies like in vitro fertilization (IVF) and intrauterine insemination (IUI) has widened the application scope of infertility drugs.

The Global Infertility Drugs Market is estimated to be valued at US$ 4262.17 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the Infertility Drugs are Koninklijke Philips N.V., LifeWatch USA, Tunstall, Apple Inc., ADT Security Services, Medical Guardian LLC, MobileHelp, Bay Alarm Company, MariCare Oy, Origin Wireless, The ADT Corporation, Singapore Technologies Electronics Limited, Semtech Corporation. These key players are focusing on expanding their production facilities and distribution network to meet the rising demand from various regions worldwide.

The growing acceptance of assisted reproductive technologies and increasing personal disposable income in developing countries has accelerated the demand for infertility drugs over the past few years. Also, the rising trend of late pregnancies due to changing lifestyle and social habits has boosted market growth. Furthermore, initiatives by public and private organizations to raise awareness about infertility treatment and management are propelling the market.

Globally, the Global Infertility Drugs Market Size is expanding tremendously, especially across regions including North America, Asia Pacific, Latin America, the Middle East & Africa. The strong presence of key manufacturers and rising infertility rates in these regions are driving the global infertility drugs market.

Market drivers

The increasing number of couples opting for IVF treatments is one of the major drivers of the infertility drugs market. Over the past decade, the success rate of IVF treatments has increased considerably owing to technological advancements. This has prompted more couples to opt for IVF methods to conceive, thereby augmenting the adoption of fertility medications and hormones that help induce and sustain pregnancy. According to reports, around 5.2 million babies were born worldwide between 2008 and 2020 through IVF treatments. This high prevalence of IVF is fueling the demand for infertility drugs used in assisted reproductive techniques.

Geopolitical Impact on Infertility Drugs Market Growth

The infertility drugs market is facing several geopolitical challenges that can impact its growth in the coming years. Rising political tensions and instability in various parts of the world like Europe, Middle East and Asia Pacific regions are causing concerns for patients seeking fertility treatments. Many couples are postponing or cancelling their plans for conception due to the uncertainty and risks involved in travelling to different countries for advanced fertility clinics and IVF procedures. This has temporarily slowed down the demand for infertility drugs. Additionally, economic sanctions and trade restrictions imposed between some countries are disrupting supply chains and availability of important infertility drugs in affected regional markets. To sustain growth, companies must consider diversifying their manufacturing and distribution networks across multiple geographies. They also need to explore partnerships with local players in emerging markets and focus on capacity building to ensure consistent supply. Telehealth and remote consultation models can help circumvent some geopolitical barriers and continue serving patients in difficult political environments.

Geographical Regions of Infertility Drugs Market Concentration

Currently, North America accounts for the largest share of the global infertility drugs market in terms of value, estimated at over 35% in 2024. This is attributed to the early adoption of advanced fertility treatments, rising insurance coverage for IVF procedures, increasing prevalence of infertility and growing awareness about family planning in countries like the US and Canada. Europe is also a major regional market for infertility drugs given the widespread availability of fertility clinics and focus on births in nations across Western and Eastern Europe. However, the Asia Pacific region is poised to show highest growth during the forecast period from 2024 to 2030, projecting a CAGR of around 8%. This growth will be fuelled by growing medical tourism, establishment of fertility chains and rising affordability of infertility treatments in highly populated countries like India and China.

Fastest Growing Region in the Infertility Drugs Market

The Asia Pacific region holds significant potential and is likely to emerge as the fastest growing regional market for infertility drugs globally between 2024-2030. Rapid socio-economic development, growing medical expenditures, increasing middle-class population and late parenthood trends are driving the demand for fertility services in Asia Pacific countries. In addition, medical tourism is positively impacting the market as many international patients travel to countries like India and Thailand for affordable IVF and other assisted reproductive technologies. Singapore, Australia and New Zealand are also witnessing a rise in the number of fertility clinics. Supported by favourable government initiatives, falling treatment costs and expanding health insurance coverage for infertility in certain nations, the Asia Pacific infertility drugs market is poised to register a strong CAGR of over 8% during the forecast period. Several global pharmaceutical companies are also focusing on this lucrative region by launching new generic infertility drugs and entering into distribution partnerships with local players.